THE NULEXA SYSTEM

The NULEXA™ system (formerly known as the VELO System under LEX Diagnostics) redefines point-of-care diagnostics by combining ultra-fast speed and high sensitivity in a PCR-based molecular system.

This breakthrough multiplex molecular diagnostics platform is the first to deliver true RT-PCR influenza A/B + SARS results in less than 10 minutes, directly from a swab sample.* The NULEXA System is CLIA waived and features proprietary technology and a cartridge-based design that eliminates the need for external liquid handling, delivering the speed, reliability and ease of use that fits seamlessly into busy point-of-care workflows.

Patients Don’t Want to Wait for Answers. Neither Do You.
The NULEXA™ System has set a new standard in molecular
RT-PCR testing for the point of care
QuidelOrtho understands that during respiratory season, every patient visit brings important decisions.
When symptoms could indicate influenza or COVID-19, patients need answers quickly so providers can make timely treatment decisions that help patients start feeling better as soon as possible. Waiting for molecular test results can delay next steps, extend patient visits and add pressure to already busy clinical workflows.
The QuidelOrtho NULEXA™ System has set a new standard for point-of-care respiratory molecular testing by being the first to deliver RT-PCR influenza + SARS results in less than 10 minutes.* That means providers can help deliver answers while patients are still in the clinic – without sacrificing the confidence of RT-PCR testing.)

* As of June 16, 2026, based on date of FDA clearance and time to result for RT-PCR Influenza A/B +
SARS-CoV-2 diagnostic tests for point-of-care settings. See the claims matrix for additional information